Objective:

To assess the impact of baseline central retinal thickness (CRT) on treatment outcomes with aflibercept 8 mg in patients with macular edema secondary to retinal vein occlusion (RVO).

Approach:

Key Findings:

• Aflibercept 8 mg improved vision and anatomy regardless of baseline CRT, based on QUASAR trial data.
• Patients receiving aflibercept 8 mg required approximately 2.5 fewer injections than those on aflibercept 2 mg.
• Visual gains were maintained through week 64, especially in branch retinal vein occlusion (BRVO) patients.
• In the highest CRT tertile, no patients on aflibercept 8 mg required monthly dosing by week 64.

Interpretation:

Conclusion:

Aflibercept 8 mg achieved significant improvements in vision and anatomy in RVO patients while requiring fewer injections compared to aflibercept 2 mg.

Sources:

• Clinical Trials at the Summit
Attribution Notice

This content is an AI-generated, fully rewritten summary based on a published scholarly article. It does not reproduce the original text and is not a substitute for the original publication. Readers are encouraged to consult the source for full context, data, and methodology.